287 related articles for article (PubMed ID: 28089247)
1. [Mid gut neuroendocrine tumors: News on medical treatment].
Dior M; Dreanic J; Prieux-Klotz C; Brieau B; Brezault C; Coriat R
Presse Med; 2017 Jan; 46(1):4-10. PubMed ID: 28089247
[TBL] [Abstract][Full Text] [Related]
2. Update on medical treatment of small intestinal neuroendocrine tumors.
Pusceddu S; Femia D; Lo Russo G; Ortolani S; Milione M; Maccauro M; Vernieri C; Prinzi N; Concas L; Leuzzi L; De Braud F; Buzzoni R
Expert Rev Anticancer Ther; 2016 Sep; 16(9):969-76. PubMed ID: 27353232
[TBL] [Abstract][Full Text] [Related]
3. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
4. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
5. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G; Padhi P; Daboul N; Monga DK
Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.
Dawod M; Gordoa TA; Cives M; De Mestier L; Crona J; Spada F; Oberg K; Pavel M; Lamarca A
Curr Treat Options Oncol; 2021 Jun; 22(8):73. PubMed ID: 34185197
[TBL] [Abstract][Full Text] [Related]
7. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
8. Biotherapies for GEP-NETs.
Öberg K
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
[TBL] [Abstract][Full Text] [Related]
9. Update in the Therapy of Advanced Neuroendocrine Tumors.
Uri I; Avniel-Polak S; Gross DJ; Grozinsky-Glasberg S
Curr Treat Options Oncol; 2017 Nov; 18(12):72. PubMed ID: 29143892
[TBL] [Abstract][Full Text] [Related]
10. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
Flaum N; Valle JW; Mansoor W; McNamara MG
Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
[TBL] [Abstract][Full Text] [Related]
11. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
Strosberg JR; Halfdanarson TR; Bellizzi AM; Chan JA; Dillon JS; Heaney AP; Kunz PL; O'Dorisio TM; Salem R; Segelov E; Howe JR; Pommier RF; Brendtro K; Bashir MA; Singh S; Soulen MC; Tang L; Zacks JS; Yao JC; Bergsland EK
Pancreas; 2017 Jul; 46(6):707-714. PubMed ID: 28609356
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
13. New perspectives in the treatment of neuroendocrine tumours.
Bajetta E; Catena L; Valente M; Bianco N; Bellomo F; Bombardieri E
Anticancer Res; 2012 Oct; 32(10):4193-200. PubMed ID: 23060539
[TBL] [Abstract][Full Text] [Related]
14. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
15. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine tumours of the small intestine.
Strosberg J
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):755-73. PubMed ID: 23582917
[TBL] [Abstract][Full Text] [Related]
17.
Daskalakis K; Norlén O; Karakatsanis A; Hellman P; Larsson R; Nygren P; Stålberg P
Endocr Relat Cancer; 2018 Apr; 25(4):471-480. PubMed ID: 29440231
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
19. Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry.
Kollar A; Bütikofer L; Ochsenbein A; Stettler C; Trepp R
Swiss Med Wkly; 2020 Jan; 150():w20176. PubMed ID: 31940430
[TBL] [Abstract][Full Text] [Related]
20. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
